While the benefit of risk-reducing surgeries in preventing second cancers in women with DCIS and PV in BRCA1 or BRCA2 are well established, preventing recurrence without overtreatment for women with PV in other genes is more challenging. This evidence concerns the gene BRCA2 and acquired polycythemia vera.